Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It provides fine chemicals and CDMO services. Zhejiang Tianyu Pharmaceutical … Read more
Zhejiang Tianyu Pharmaceutical Co Ltd (300702) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.84 Billion CNY
Based on the latest financial reports, Zhejiang Tianyu Pharmaceutical Co Ltd (300702) has total liabilities worth CN¥2.84 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Tianyu Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Zhejiang Tianyu Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Tianyu Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Tianyu Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bata India Limited
NSE:BATAINDIA
|
India | ₹21.67 Billion |
|
Hangzhou Advance Gearbox Group Co Ltd
SHG:601177
|
China | CN¥2.46 Billion |
|
Puregold Price Club Inc
PINK:PGCMF
|
USA | $90.88 Billion |
|
Hubeiyichang Transportation Group Co Ltd
SHE:002627
|
China | CN¥767.49 Million |
|
Nanjing Xinjiekou Department Store Co Ltd
SHG:600682
|
China | CN¥6.98 Billion |
|
Galimmo SA
PA:GALIM
|
France | €364.12 Million |
|
W-SCOPE Corporation
PINK:WSPCF
|
USA | $10.34 Billion |
|
Leshan Electric Power Co Ltd
SHG:600644
|
China | CN¥2.28 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Zhejiang Tianyu Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Tianyu Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Tianyu Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total liabilities of Zhejiang Tianyu Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.08 Billion | +8.08% |
| 2023-12-31 | CN¥2.85 Billion | -2.41% |
| 2022-12-31 | CN¥2.92 Billion | +39.66% |
| 2021-12-31 | CN¥2.09 Billion | +55.74% |
| 2020-12-31 | CN¥1.34 Billion | +67.21% |
| 2019-12-31 | CN¥803.09 Million | -32.11% |
| 2018-12-31 | CN¥1.18 Billion | +44.43% |
| 2017-12-31 | CN¥818.99 Million | -9.77% |
| 2016-12-31 | CN¥907.72 Million | +9.29% |
| 2015-12-31 | CN¥830.58 Million | +32.12% |
| 2014-12-31 | CN¥628.67 Million | +21.34% |
| 2013-12-31 | CN¥518.11 Million | -- |